 Item 2.
Consequently, no forward-looking statement can be guaranteed.
Overview.
The Company reflected a loss before income tax benefit of $290,100 for the six months ended December 31, 2017 compared to $4,700 for the six months ended December 31, 2016 mainly due to decreased catalyst research instrument sales and product development costs as previously discussed.
The results reflected total non-cash amounts for depreciation and amortization of $77,000 and $154,100 for the three and six month periods ended December 31, 2017 compared to $93,800 and $189,500 for the corresponding three and six month periods in 2016.
The benchtop laboratory equipment sales reflected $359,900 of Torbal brand product sales for the three months ended December 31, 2017, compared to $303,500 in the three months ended December 31, 2016.
As of December 31, 2017, the order backlog for catalyst research instruments was $752,500, all of which is expected to be shipped during fiscal year ending June 30, 2018, compared to $397,300 as of December 31, 2016.
The overall gross profit percentage for the three months ended December 31, 2017 was 40.5% compared to 29.6% for the three months ended December 31, 2016.
The catalyst research instruments was negatively impacted by the lower sales.
General and administrative expenses for the three months ended December 31, 2017 amounted to $407,900 compared to $409,200 for the three months ended December 31, 2016.
Selling expenses for the three months ended December 31, 2017 decreased $9,600 (4.3%) to $214,600 from $224,200 for the three months ended December 31, 2016, due to lower sales related expenses for the Catalyst Research Instruments Operations.
Research and development expenses increased by $27,900 (26.6%) to $132,900 for the three months ended December 31, 2017 compared to $105,000 for the three months ended December 31, 2016, primarily due to increased new product development costs incurred by the Benchtop Laboratory Equipment Operations related to the Torbal Scales Division.
Total other income decreased by $2,200 (26.5%) from $8,300 for the three months ended December 31, 2016 to $6,100 for the three months ended December 31, 2017 due to lower interest on its investment securities.
The Company reflected an income tax expense of $97,400 for the three months ended December 31, 2017 compared to income tax expense of $19,500 for the three months ended December 31, 2016, primarily due to a revision of the estimate of the Company's expected annual income.
As a result of the foregoing, the Company recorded a net loss of $81,000 for the three months ended December 31, 2017 compared to net income $45,300 for the three months ended December 31, 2016.
The Six Months Ended December 31, 2017 Compared with The Six Months Ended December 31, 2016 



 Net revenues for the six months ended December 31, 2017 decreased $1,069,600 (25.2%) to $3,173,300 from $4,242,900 for the six months ended December 31, 2016, reflecting a decrease of $1,087,300 in net sales of catalyst research instruments due to decreased orders from Original Equipment Manufacturer OEM customers and lack of large orders, and a decrease of $38,000 in sales of benchtop laboratory equipment derived from the Torbal Division, partially offset by a $55,700 increase in bioprocessing royalties.
The benchtop laboratory equipment sales reflected $664,200 of Torbal brand product sales for the six months ended December 31, 2017, compared to $685,500 in the six months ended December 31, 2016.
The overall gross profit percentage for the six months ended December 31, 2017 was 38.4% compared to 34.5% for the six months ended December 31, 2016 as a result of the Benchtop Laboratory Equipment Operations (which is sold at higher margins) consisting of a higher percentage of total sales for the year.
General and administrative expenses for the six months ended December 31, 2017 increased slightly by $14,700 (1.8%) to $836,300 compared to $821,600 for the six months ended December 31, 2016.
Selling expenses for the six months ended December 31, 2017 decreased $25,300 (5.7%) to $415,600 from $440,900 for the six months ended December 31, 2016, due to lower sales related expenses for the Catalyst Research Instruments Operations.
12  



 Research and development expenses increased by $41,600 (18.9%) to $262,000 for the six months ended December 31, 2017 compared to $220,400 for the six months ended December 31, 2016, primarily due to increased new product development costs incurred by the Benchtop Laboratory Equipment Operations related to the Torbal Scales Division.
Total other income decreased by $7,300 (53.3%) from $13,700 for the six months ended December 31, 2016 to $6,400 for the six months ended December 31, 2017 due to lower interest on its investment securities and miscellaneous income items.
As a result of the foregoing, the Company recorded a net loss of $313,600 for the six months ended December 31, 2017 compared to $3,400 for the six months ended December 31, 2016.
Liquidity and Capital Resources.
Cash and cash equivalents decreased by $324,400 to $700,700 as of December 31, 2017 from $1,025,100 as of June 30, 2017 primarily due to decreased cash generated by the Catalyst Research Instrument Operations and increased inventories.
Net cash used in operating activities was $133,700 for the six months ended December 31, 2017 compared to $450,300 used during the six months ended December 31, 2016.
Net cash used in investing activities was $84,600 for the six months ended December 31, 2017 compared to $27,000 used during the six months ended December 31, 2016 principally due to new capital equipment purchased during the current year period by the Benchtop Laboratory Equipment Operations.
The Company used $106,100 in financing activities in the six months ended December 31, 2017 compared to cash provided of $129,400 in the six months ended December 31, 2016 mainly due to decreased proceeds under the line of credit in the current year.
The Company's working capital decreased by $191,500 to $3,782,400 as of December 31, 2017 compared to $3,973,900, as of June 30, 2017 due to increased capital expenditures and a net loss incurred during the current period.
The Company has a Demand Line of Credit through June 2018 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently 4.5%.
Advances on the line, are secured by a pledge of the Company’s assets including inventory, accounts, chattel paper, equipment and general intangibles of the Company.
As of December 31, 2017 $40,000 which was borrowed by our subsidiary, Altamira Instruments, was outstanding under such line.
In addition, the Company utilized $245,400 of its borrowing availability under the line as collateral for a warranty standby letter of credit required during a two year warranty period as a condition of sale for a large order of catalyst research instruments shipped in a prior fiscal year and installed in the first quarter of fiscal 2018, leaving an available borrowing balance of $14,600 under the line of credit.
Management believes that the Company will be able to meet its cash flow needs during the 12 months ending June 30, 2018 from its available financial resources including its line of credit, its cash and investment securities, and operations.
13  



 Item 4.
Controls and Procedures 



  Evaluation of Disclosure Controls and Procedures.
As of the end of the period covered by this report, based on an evaluation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), the Chief Executive and Chief Financial Officer of the Company has concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in its Exchange Act reports is recorded, processed, summarized and reported within the applicable time periods specified by the SEC's rules and forms.
Changes in Internal Control Over Financial Reporting.
PART II – OTHER INFORMATION 



 Item 6.
Exhibits and Reports on Form 8-K 



 [DATA_TABLE_REMOVED]  



 Reports on Form 8-K: None 



14  



  SIGNATURE 



 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
[DATA_TABLE_REMOVED]  



15
